IP Library Patent Application 11377693
Patent Application
App. No. 11/377,693

Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/377,693
Abstract

The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate; a second phase of two groups of daily dosage units, which consist of a first group containing 5 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 2 mg of dienogest, and a second group containing 17 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily dosage units each consisting of 1 mg of estradiol valerate; and another phase of 2 daily dosage units of a pharmaceutically harmless placebo; so that the multiphase combination preparation consists of a total number of 28 daily dosage units.

Claims (10)

1 . A multiphase combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding, said combination preparation containing

a first phase of two daily dosage units, each of which consist of 3 mg of estradiol valerate;

a second phase of two groups of daily dosage units, said two groups consisting of a first group containing 5 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 2 mg of dienogest, and a second group containing 17 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 3 mg of dienogest;

a third phase of two daily dosage units, each consisting of 1 mg of estradiol valerate; and

another phase of two daily dosage units, each consisting of a pharmaceutically harmless placebo;

so that the multiphase combination preparation consists of a total number of 28 daily dosage units.

2 . A method of treating dysfunctional uterine bleeding and of oral contraception, said method comprising the steps of:

a) providing a multiphase combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding, said combination preparation containing a first phase of two daily dosage units each consisting of 3 mg of estradiol valerate; a second phase of two groups of daily dosage units, said two groups consisting of a first group containing 5 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 2 mg of dienogest, and a second group containing 17 daily dosage units, each of which consist of a combination of 2 mg of estradiol valerate and 3 mg of dienogest; a third phase of 2 daily dosage units with 1 mg of estradiol valerate; and another phase of 2 daily dosage units of a pharmaceutically harmless placebo; so that the multiphase combination preparation consists of a total number of 28 daily dosage units; and

b) administering said multiphase combination preparation to a woman in need of treatment for dysfunctional uterine bleeding over at least one treatment cycle.

3 . The method as defined in claim 2 , wherein said at least one treatment cycle consists of six treatment cycles.

Assignments (2)
CHANGE OF NAME Recorded Oct 23, 2009
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023414/0410 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2006
From: ZEUN, SUSAN; BOUNDES, POL; SECCI, ANGELO; ENDRIKAT, JAN; ZIMMERMANN, HOLGER
To: SCHERING AG
Reel/Frame 017771/0703 →